An International Publisher for Academic and Scientific Journals
Author Login 
SAS Journal of Medicine | Volume-9 | Issue-09
Immune Response to SARS-Covid 19 Vaccine in Patients with Cancer: Prospective Study at the Oncology-Radiotherapy Department/Oncology and Hematology Hospital of Marrakech
Bounid Oumayma, El Matlini Abdelali, Darfaoui Mouna, El Omrani Abdelhamid, Khouchani Mouna
Published: Sept. 15, 2023 | 106 100
DOI: 10.36347/sasjm.2023.v09i09.015
Pages: 997-1000
The world has experienced the SARS-Covid 19 virus disease pandemic since 2019, which has required the implementation of multiple preventive measures aimed at protecting against this infection may be serious in patients at risk, in particular cancer patients (high incidence of immunosuppression and comorbidities). In Morocco, the anti-Covid 19 vaccination started in January 2021. The scientific committee recommended the vaccination of all cancer patients using two doses except for under-vaccinated patients. We carried out a prospective observational study with 30 patients followed in our center and received an anti-Covid 19 vaccination for a period of four months. The objectives of our study were to evaluate the qualitative immunological response in this population at risk and to review the tolerance of vaccination. We conducted a prospective observational study about 30 patients followed in the Oncology-Radiotherapy department at the Hospital of Oncology and Hematology of Marrakech, a recruitment from different sites of our department was done: medical consultation, outpatient clinic, hospitalization unit and at the radiotherapy technical platform for a period of four months (from May 3, 2021 to August 31, 2021). We recruited 36 patients from different departments of our center, the average age of our patients was 49 years [38-67]. Breast location was dominant (22%) followed by UCNT (16%). The localized stage of the disease was the most frequent (88%). At the time of recruitment, 44% of patients were undergoing radiotherapy, 38% were receiving chemotherapy, 16% hormone therapy and 11% of patients were undergoing post-treatment follow-up. Six of our patients (16%) had seropositivity before receiving the first vaccine dose indicating a latent infection and were excluded from our series. All our patients received the Synopharm® vaccine. After the first vaccine dose, 04 patients (13%) showed positive serology in favor of a vaccine response, while 07 patients (23%) .....